Posted: Tuesday, January 25, 2022
Evidence of antitumor activity against hormone receptor–positive, HER2-negative breast cancer was shown with the first-in-class CDK7 inhibitor samuraciclib in combination with fulvestrant. Charles Coombes, MD, PhD, of the Imperial College in London, United Kingdom, presented these findings on behalf of his colleagues at the 2021 San Antonio Breast Cancer Symposium (SABCS; Abstract GS3-10).
This single-arm cohort study enrolled 31 patients with advanced hormone receptor–positive, HER2-negative breast cancer. All patients had previously been treated with an aromatase inhibitor and a CDK4/6 inhibitor for advanced disease. Patients received the standard dose of fulvestrant with either 240 mg of oral samuraciclib (6 patients) or 360 mg of oral samuraciclib (25 patients).
The most common grade 1 or 2 adverse drug reactions were nausea, vomiting, and diarrhea. In addition, most patients remained on treatment until disease progression. Evaluation of efficacy using Response Evaluation Criteria in Solid Tumors version 1.1 showed evidence of reduction in tumor disease burden, which included a partial response in one patient who has been receiving this therapy for approximately 1 year.
Disclosure: For a full list of authors’ disclosures, visit abstractsonline.com.
2021 San Antonio Breast Cancer Symposium